drugset / Trial / NCT05248945
DDI Study of Evobrutinib and Carbamazepine
Phase 1
Completed
14 enrolled
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelOther
Summary
The purpose of this study was to investigate the effect of multiple doses of carbamazepine on two single doses of evobrutinib pharmacokinetics (PK) in healthy participants. Study details included: Study Duration: up to 54 days. Treatment Duration: 25 days. Visit Frequency: Participants were residents in the Clinical Research Unit from Day 1 to Day 20 and returned on Day 26 for a Safety Follow-Up visit.
Timeline
- Start
- 2022-01-13
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | 300 mg | — |
| Subject | Evobrutinib | Small molecule | 45 mg | Oral |
Indications
No indication recorded.